Simeon J. George, M.D., M.B.A. has served on our Board of Directors since April 2015. He is the Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic biotech venture capital firm, a role he has held since September 2020. Prior to leading SR One as an independent firm, Dr. George served as Chief Executive Officer and President of S.R. One, Limited (now GSK Equity Investments, Limited), an indirect, wholly owned subsidiary of GlaxoSmithKline plc, where he had been employed since 2007.
Dr. George co-founded Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, and currently serves on its board of directors—a position he has held since February 2020 (and previously from July 2015 to September 2017). He also serves on the board of Design Therapeutics, Inc. (DSGN), another clinical-stage biopharmaceutical company. Previously, Dr. George has served on the boards of Principia Biopharma Inc., Progyny, Inc. (PGNY), and Turning Point Therapeutics, Inc., among others.
Earlier in his career, Dr. George worked as a consultant at Bain & Company and in investment banking at Goldman Sachs. He earned his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the Wharton School of the University of Pennsylvania. He also holds a B.A. in Neuroscience from Johns Hopkins University.
What is Simeon George's net worth?
The estimated net worth of Simeon George is at least $100.66 million as of July 16th, 2025. Dr. George owns 1,730,179 shares of CRISPR Therapeutics stock worth more than $100,661,814 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. George may own. Learn More about Simeon George's net worth.
How do I contact Simeon George?
Has Simeon George been buying or selling shares of CRISPR Therapeutics?
Simeon George has not been actively trading shares of CRISPR Therapeutics within the last three months. Most recently, on Wednesday, July 16th, Simeon George bought 989,812 shares of CRISPR Therapeutics stock. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the transaction, the director now directly owns 1,730,179 shares of the company's stock, valued at $90,021,213.37. Learn More on Simeon George's trading history.
Who are CRISPR Therapeutics' active insiders?
CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Simeon George (Director), John Greene (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Naimish Patel (Chief Medical Officer), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?
In the last year, CRISPR Therapeutics insiders bought shares 2 times. They purchased a total of 996,812 shares worth more than $51,813,868.36. In the last year, insiders at the sold shares 8 times. They sold a total of 92,526 shares worth more than $5,560,017.15. The most recent insider tranaction occured on October, 17th when CEO Samarth Kulkarni sold 50,895 shares worth more than $3,456,279.45. Insiders at CRISPR Therapeutics own 4.3% of the company.
Learn More about insider trades at CRISPR Therapeutics. Information on this page was last updated on 10/17/2025.
